Phaseline

Targets › ALB

ALB (Albumin): drug programs, companies and trials

8 programs from 8 companies in 10 trials: 5 Phase 3, 4 Phase 2, 1 Phase 4; Gastroenterology, Metabolic and endocrine, Oncology; next expected readout Dec 2026.

Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). (UniProt, P02768)

Open in Phaseline: the race on ALB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cheng QiRice-derived recombinant human serum albumin (OsrHSA)
Recombinant human serum albumin produced in rice plants
ALBPhase 4Post-hepatectomy HypoalbuminemiaJul 2027
Democritus University of ThraceHuman albumin
Intravascular volume expander to prevent reflex renal vasoconstriction during diuresis
ALBPhase 3Diuretics Drug ReactionsDec 2026
AstraZenecaCAEL-101
monoclonal antibody against misfolded light chain amyloid deposits
ALBPhase 3AL AmyloidosisApr 2027
Capital Medical University25% human albumin
Plasma volume expansion and neuroprotection in acute ischemic stroke
ALBPhase 3Acute Ischemic StrokeJun 2027
Aleksander KragHuman albumin
Human serum albumin protein replacement therapy
ALBPhase 3Decompensated Cirrhosis and Ascites–
Hunter Holmes Mcguire Veteran Affairs Medical CenterAlbumin Infusion (Albutein)
Intravenous human serum albumin
ALBPhase 2CirrhosisDec 2026
Anahita Rabiee MD MHSAlbumin infusion (25% albumin)
Osmotic diuretic and oncotic pressure modulator
ALBPhase 2CirrhosisDec 2026
The First Hospital of Jilin UniversityHuman Serum Albumin Infusion (LAT Group)
Albumin replacement therapy - maintaining serum albumin levels above 25 g/L
ALBPhase 2Postoperative Hypoalbuminemia–

Conditions

AL Amyloidosis (2) Postoperative Hypoalbuminemia (2) Cirrhosis (2) Post-hepatectomy Hypoalbuminemia (1) Diuretics Drug Reactions (1) Acute Ischemic Stroke (1) Decompensated Cirrhosis and Ascites (1)

Modalities

protein or peptide (6), small molecule (1), mixed (1)

Companies

AstraZeneca (1) Cheng Qi (1) The First Hospital of Jilin University (1) Democritus University of Thrace (1) Hunter Holmes Mcguire Veteran Affairs Medical Center (1) Capital Medical University (1) Aleksander Krag (1) Anahita Rabiee MD MHS (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.